Advertisement
RESEARCH ARTICLE
A lineage-tracing tool to map the fate of hypoxic tumour cells
Jenny A. F. Vermeer, Jonathan Ient, Bostjan Markelc, Jakob Kaeppler, Lydie M. O. Barbeau, Arjan J. Groot, Ruth J. Muschel, Marc A. Vooijs
Disease Models & Mechanisms 2020 13: dmm044768 doi: 10.1242/dmm.044768 Published 30 July 2020

Handling Editor: Elaine R. Mardis

ABSTRACT

Intratumoural hypoxia is a common characteristic of malignant treatment-resistant cancers. However, hypoxia-modification strategies for the clinic remain elusive. To date, little is known on the behaviour of individual hypoxic tumour cells in their microenvironment. To explore this issue in a spatial and temporally controlled manner, we developed a genetically encoded sensor by fusing the O2-labile hypoxia-inducible factor 1α (HIF-1α) protein to eGFP and a tamoxifen-regulated Cre recombinase. Under normoxic conditions, HIF-1α is degraded but, under hypoxia, the HIF-1α-GFP-Cre-ERT2 fusion protein is stabilised and in the presence of tamoxifen activates a tdTomato reporter gene that is constitutively expressed in hypoxic progeny. We visualise the random distribution of hypoxic tumour cells from hypoxic or necrotic regions and vascularised areas using immunofluorescence and intravital microscopy. Once tdTomato expression is induced, it is stable for at least 4 weeks. Using this system, we could show in vivo that the post-hypoxic cells were more proliferative than non-labelled cells. Our results demonstrate that single-cell lineage tracing of hypoxic tumour cells can allow visualisation of their behaviour in living tumours using intravital microscopy. This tool should prove valuable for the study of dissemination and treatment response of post-hypoxic tumour cells in vivo at single-cell resolution.

This article has an associated First Person interview with the joint first authors of the paper.

INTRODUCTION

Many solid tumours contain areas of hypoxia, which is the result of O2 demand (rapid proliferation) exceeding O2 supply (aberrant vasculature) (Thomlinson and Gray, 1955; Brahimi-Horn et al., 2007). Owing to limits on O2 diffusion from the blood vessels, tumours experience chronic hypoxia and necrosis in regions distant from the vasculature. Acute or cycling hypoxia also occurs in tumours due to temporary occlusion of blood vessels obstructing perfusion leading to areas of hypoxia, which become re-oxygenated when the obstruction is relieved (Dewhirst, 2009; Salem et al., 2018). Tumour hypoxia is strongly associated with a worse outcome in many different cancers irrespective of treatment (Vaupel and Mayer, 2007), and tumour hypoxia is a direct factor in resistance to some chemotherapy and radiation therapy. Direct O2 measurements in clinical studies using oxygen needle electrodes indicate that hypoxia is strongly associated with local regional control in head and neck squamous cell carcinoma (Nordsmark et al., 2005), prostate (Milosevic et al., 2012) and cervix (Fyles et al., 1998) cancer patients treated with radiotherapy. Hypoxia imaging using positron emission tomography tracers such as 18F-Hx4,18F-MISO and 18F-FAZA have demonstrated strong associations of tracer uptake with outcome (Lehtiö et al., 2004; Dubois et al., 2011; Fleming et al., 2015).

The main adaptive response to hypoxia is the stabilisation of the oxygen-regulated hypoxia inducible factor alpha (HIF-α) proteins HIF-1α, HIF-2α and HIF-3α. HIF-α proteins are predominantly regulated post-translationally through oxygen-dependent prolyl and asparagine hydroxylases, which hydroxylate specific proline and asparagine residues on the HIF-α oxygen-dependent degradation (ODD) domain. Hydroxylation of asparagine inhibits the recruitment of the transcriptional regulator p300 (also known as EP300). Prolyl hydroxylation promotes interaction with the von Hippel-Lindau (pVHL; VHL) protein, which recruits an E3 ubiquitin ligase, targeting HIF-α for proteasomal degradation (Ivan et al., 2001). Under hypoxic conditions, the activity of prolyl and asparagine hydroxylases is attenuated, leading to accumulation of HIF-α proteins. HIF-α then translocates to the nucleus, where it binds the constitutively expressed HIF-1β protein and the co-activator p300. The HIF transcriptional complex is known to transactivate over 1500 target genes through binding to hypoxia response elements (HREs) located in the target genes or flanking sequences (Prabhakar and Semenza, 2015). HIF target genes play a role in a broad range of pathways including those involved in angiogenesis (VEGF; VEGFA), metabolism (GLUT-1; SLC2A1), cell proliferation (TGF-α), cell adhesion (MIC2; CD99), pH regulation (CAIX; CA9) and cell survival (TGF-α) among others (Jubb et al., 2010; Wilson and Hay, 2011; Muz et al., 2015; LaGory and Giaccia, 2016). It has long been known that the concentration of oxygen within the tumour correlates with the efficacy of radiotherapy (Gray et al., 1953). HIF-α proteins can be stabilised in relatively mild hypoxia; however, much more severe hypoxia plays a larger role in radiotherapy resistance due to the decreased effectiveness of radiotherapy at these very low oxygen conditions. Even so, hypoxia and higher levels of HIF are associated with, and their presence also correlates with, more aggressive tumours, therapy resistance, immunosuppression, metastasis and poor prognosis (LaGory and Giaccia, 2016). Elevated HIF-1α and HIF-2α levels have also been shown to be associated with poor prognosis in a number of cancers (Giatromanolaki et al., 2001; Ioannou et al., 2009; Zheng et al., 2013; Ren et al., 2016; Roig et al., 2018).

Because of its strong correlation with adverse patient outcome, hypoxic modification in tumours has been an area of intense basic and translational research and drug development. A systematic review of 10,108 patients across 86 trials that were designed to modify tumour hypoxia in patients that received primary radiotherapy alone showed that overall modification of tumour hypoxia significantly improved the effect of radiotherapy but had no effect on metastasis (Overgaard, 2007).

Accelerated radiotherapy with carbogen and nicotinamide (ARCON), which increases tumour oxygenation to improve radiotherapy treatment, has shown limited success in a Phase III clinical trial. ARCON improved 5-year regional control specifically in patients with hypoxic tumours; however, no improvement in disease-free or overall survival was found (Janssens et al., 2012).

The hypoxia-activated pro-drug evofosfamide was studied in a Phase III clinical trial. Evofosfamide improved progression-free survival as well as higher objective response rate; however, the trial failed as the primary endpoint (overall survival time) was not significantly improved (Van Cutsem et al., 2016). Unfortunately, while a few clinical trials have been successful, many hypoxia modification or targeting trials have failed because of underpowered studies and the lack of hypoxia biomarkers to stratify responders among others (Spiegelberg et al., 2019).

Although many of the molecular mechanisms of how cells respond to hypoxia are known, how the hypoxic cells contribute to poor prognosis is still poorly understood. It is known that hypoxic cells are more resistant to treatment and more likely to disseminate and develop into metastases (Harada et al., 2012; Muz et al., 2015; Godet et al., 2019). However, a direct demonstration of the cell-autonomous phenotypes of hypoxic tumour cells within the primary tumour and their interplay with the tumour microenvironment remains understudied.

Using the ODD domain of the HIF-1α protein as an oxygen sensor fused to a tamoxifen-inducible CreERT2 recombinase, Harada et al. (2012) elegantly used lineage tracing of hypoxic cells and their progeny in colon carcinoma xenografts. They showed that hypoxic cells were able to survive irradiation and formed a large proportion of the recurrent tumour after 25 Gy irradiation. High HIF-1 activity was also found in cells that experience radiation-induced re-oxygenation. HIF-1-positive cells after irradiation-induced re-oxygenation also translocated towards blood vessels and this translocation was suppressed by HIF inhibitors. Godet et al. (2019) recently showed, through an alternative hypoxia lineage-tracing system, that post-hypoxic tumour cells in mice maintain a reactive oxygen species (ROS)-resistant phenotype. This provides a survival advantage in the blood stream, therefore promoting their ability to form distant metastases. One limitation of the aforementioned systems is the relatively long time in continuous hypoxia needed before labelling of cells was achieved, limiting the systems predominantly to areas of sustained chronic hypoxia. These studies also did not visualise individual hypoxic tumour cells within the tumour microenvironment.

In this present study, we developed an alternative approach to lineage trace the fate of hypoxic tumour cells that directly reports HIF-1α stabilisation rather than the hypoxia transcriptional response. The continuous expression of the system we created allows the identification of cells experiencing acute as well as chronic hypoxia and is achieved through a genetically encoded hypoxia sensor composed of a GFP-tagged HIF-ODD-GFP-CreERT2 fusion protein, herein known as MARCer. Once HIF-1α is stabilised, the addition of tamoxifen leads to the Cre-mediated activation of a ubiquitously expressed tdTomato, labelling hypoxic cells and their progeny. These fluorescent markers enabled intravital imaging using window chambers (Kedrin et al., 2008), tracing the fate of hypoxic tumour cells at the single-cell level within the primary tumour.

RESULTS

Hypoxia induces eGFP and tdTomato expression in HIF-MARCer reporter cells

To establish a HIF-cell-tracing method (HIF-MARCer) amenable for in vivo hypoxia imaging, H1299 non-small cell lung carcinoma cells were transduced with HIF-1α-eGFP-CreERT2 complementary DNA (cDNA) (MARCer fusion protein) expression vector and with a loxP-flanked STOP tdTomato cassette (H1299-MR cells; Fig. 1A). Thus, under hypoxia, the tamoxifen-regulated HIF-Cre fusion protein will excise the STOP cassette leading to tdTomato expression, which will persist under normoxia. To test this system, H1299-MARCer cells were exposed to hypoxia (0.2% O2) or deferoxamine mesylate (DFO; a hypoxia mimetic) in vitro, resulting in induction of eGFP and HIF-1α protein expression, which was degraded within minutes after re-exposure to normoxia and corresponded with the levels of the endogenous HIF-1α protein (Fig. 1B,C).

Fig. 1.
Fig. 1.

H1299-MARCer reporter (H1299-MR) cells were created. (A) Constructs used for transduction of H1299 cells. (B) Western blot analysis of HIF-1α-MARCer and endogenous HIF-1α (HIF-1α-E) after exposure of H1299-MARCer cells to hypoxia (0.2% O2) in vitro and re-oxygenation. Lamin A was used as a loading control and the HIF-stabilising agent DFO was used as a positive control. (C,D) Fluorescence-activated cell sorting (FACS) plots of eGFP and tdTomato expression after exposure to hypoxia (0.1% O2) for 24 h (C, left) and 24 h of hypoxia followed by 24 h of re-oxygenation (D, left). Representative images of MARCer stabilisation via eGFP taken after 24 h exposure to hypoxia (0.2% O2) (C, right) and after a further 24 h of re-oxygenation of tdTomato expression (D, right) are also shown. Scale bars: 200 µm. (E) Flow cytometric analysis of eGFP and tdTomato expression after exposure to increasing times of hypoxia (0.1% O2) in the presence of 4-hydroxytamoxifen (4-OHT). Time point ‘0’ is showing cells cultured under normoxia in the presence of 4-OHT for 24 h. Dots represent independent experiments carried out in duplicate and coloured bars indicate averages. ##P<0.01 indicates a difference in tdTomato expression between no hypoxia and 2 h, and ###P<0.001 shows the difference in tdTomato expression for 0 versus 4, 6, and 24 h. *P<0.05 and **P<0.01 show a difference for eGFP expression as indicated, and ***P<0.001 indicates a significantly higher eGFP expression after 24 h compared to 0, 2 and 4 h, as calculated by one-way ANOVA followed by Bonferroni's multiple comparison. (F) Flow cytometric analysis of eGFP and tdTomato expression after exposure to 24 h hypoxia (0.1% O2) followed by increasing times of re-oxygenation. It should be noted that time point ‘0’ is showing the same data presented in E as 24 h. Dots represent independent experiments carried out in duplicate and coloured bars indicate averages.

H1299-MR cells were also cultured under hypoxia in the presence of 4-hydroxytamoxifen (4-OHT) (Fig. 1D; Fig. S1B), and eGFP and tdTomato expression were measured by flow cytometry (Fig. 1C-F). Hypoxia (0.1% O2) induced the expression of eGFP from 6 h of treatment onwards (Fig. S1A,C,E). MARCer stabilisation is visualised through eGFP expression after 24 h exposure to hypoxia (0.2%, Fig. 1C) and cytoplasmic distribution of eGFP after treatment with DFO is visualised in Fig. S1D. tdTomato expression was not visible immediately after exposure to hypoxia and was therefore assessed after re-oxygenation for up to 24 h, and until then tdTomato expression kept increasing, whereas eGFP rapidly decreased upon re-oxygenation (Fig. 1D,F; Fig. S1B). In the absence of 4-OHT, tdTomato expression was not induced (Fig. S1C,F). The HIF-1 target gene VEGF was induced by 0.2% hypoxia and 4-OHT only slightly further induced these levels (Fig. S1E).

Once tdTomato expression was induced, it was stably expressed in H1299-MR cells under normoxic conditions in the absence of 4-OHT for up to at least 4 weeks (Fig. S1F). When tdTomato+ cells were re-exposed to hypoxia, tdTomato expression remained stable (Fig. S1G); however, the fluorescence intensity gradually and significantly declined over time (Fig. S1H).

We conclude that the HIF MARCer allele reliably reports on endogenous hypoxia and HIF activity, and only slightly increases the HIF transcriptional response when 4-OHT is present. By stably inducing tdTomato expression upon administration of tamoxifen we created a reliable tracer of cells exposed to hypoxia with little background fluorescence.

A single administration of tamoxifen induces tdTomato expression in H1299-MR xenografts

H1299-MR cells were injected subcutaneously into the flank of female Balb/c nude mice to grow as xenografts. Once tumour size reached ∼100 mm3, tamoxifen was administered by oral gavage and eGFP and tdTomato expression were assessed by flow cytometry 2 days later (Fig. 2A). eGFP expression could not be detected as this is rapidly degraded after exposure to oxygen (Fig. 1B,F) during sample processing. tdTomato was induced by both 5 mg and 10 mg tamoxifen, and 10 mg was used in further experiments as expression appeared more robust (Fig. 2A). tdTomato expression was followed over time and significantly induced from 5 days after tamoxifen administration onwards and expression did not significantly increase beyond 5 days (Fig. 2B).

Fig. 2.
Fig. 2.

eGFP and tdTomato expression and quantification of immunofluorescent staining of H1299-MR xenografts. (A) One single administration of tamoxifen by oral gavage induced tdTomato expression in H1299-MR xenografts as measured by flow cytometry 2 days after administration. Dots represent individual mice and bars indicate averages. (B) From 5 days after administration of 10 mg tamoxifen, tdTomato expression was significantly induced. ###P<0.001 compared to no tamoxifen, ***P<0.001 as determined by one-way ANOVA and Bonferroni's multiple comparison. (C) Micrograph of EF5 staining showing a necrotic area (dashed line) surrounded by close and more distant EF5+ staining. Scale bar: 30 µm. (D) EF5 quantification showing hypoxic area as a percentage of total tumour area. (E) Distance of tdTomato+ cells to EF5+ areas normalised to all cells (Hoechst; Fig. S2C). (F) Cells inside hypoxic areas as a percentage of all cells or tdTomato+ cells. (G) CD31 staining showing vessel density as a percentage of total tumour area. (H) Distance of tdTomato+ to CD31+ areas normalised to all cells (Hoechst; Fig. S2D). For staining (D-H), one to five sections per tumour, separated by ∼1 mm, were analysed and the average was indicated by the dots, whereas the bars indicate the average of all mice in the group. TAM, tamoxifen.

tdTomato expression does not significantly correlate with severe hypoxia

To assess whether expression of tdTomato correlated with the extent of hypoxia and vascularisation, we stained frozen tumour sections for EF5 (an exogenous hypoxia marker) (Fig. 2C; Fig. S2A) and CD31 (PECAM1) (Fig. S2B). The EF5+ area did not change over time (Fig. 2D) and did not significantly correlate with tumour size as assessed by a Pearson correlation test on all time points combined (Fig. S3A). EF5+ areas were located both in proximity to and more distant from necrotic areas (Fig. 2C; Fig. S2A). The distance of tdTomato+ cells to EF5+ regions was not different from the general population, nor did it change over time (Fig. 2E; Fig. S2C). tdTomato+ cells were also equally likely to be inside an EF5+ area as the total cell population (Fig. 2F). From these results we conclude that post-hypoxic cells are not more likely to reside in hypoxic areas than other tumour cells. Also, the number of tdTomato+ cells did not correlate with the EF5+ area for any of the assessed time points (Fig. S3B). Finally, eGFP+ cells were occasionally visible (Fig. 2C; Fig. S2A,B). Quantification of eGFP expression appeared impossible due to high autofluorescence of necrotic areas (Fig. 2C, dashed line), and staining for GFP protein did not clearly improve eGFP+ cell detectability (not shown).

Tumour sections were stained for CD31 (Fig. S2B) and the percentage of the tumour area covered by vessels was determined. The percentage of vessel area did not change over time (Fig. 2G), nor did the closest distance of each of the tdTomato+ cells or of all cells to the nearest vessel (Fig. 2H; Fig S2D). Surprisingly, the total areas of EF5 and CD31 positivity did not significantly correlate (Pearson correlation test on all time points combined, Fig. S3C), as we would expect a larger EF5+ area to correlate with a lower vessel density and therefore the CD31 area. This could be due to areas of increased oxygen demand, limited perfusion or vessel leakiness, in addition to cycling hypoxia.

RFP staining and tdTomato fluorescence show a similar expression pattern after administration of tamoxifen

Tumour sections were stained using antibodies against RFP by immunofluorescence in order to detect the tdTomato protein (Fig. S4). More RFP+ cells were detected by immunofluorescence than by imaging intrinsic tdTomato, indicating that not all tdTomato+ cells are detected by direct fluorescence (Fig. 3A). However, tdTomato fluorescence and RFP immunofluorescence showed a strong correlation (Fig. 3B) and the same expression pattern after tamoxifen (Fig. 3A), a trend that was also similar to tdTomato detection by flow cytometry (Fig. 3C). With imaging on consecutive sections, tdTomato+ and RFP+ cells were equally likely to be detected inside or outside EF5+ areas (Fig. 3D). Therefore, even though not all tdTomato cells can be detected with a certain method, this should not introduce bias with regard to lineage tracing of hypoxic cells.

Fig. 3.
Fig. 3.

Immunofluorescent staining of H1299-MR xenografts. (A) Quantification of RFP staining showing that more tdTomato+ cells can be detected after staining than when only intrinsic tdTomato was imaged by epifluorescence microscopy. Dots represent the average of one to five sections per tumour, separated by ∼1 mm. ***P<0.001 as determined by two-way ANOVA followed by Bonferroni's multiple comparison. (B) RFP staining and intrinsic tdTomato on frozen sections significantly correlate. (C) RFP staining and intrinsic tdTomato significantly correlate with tdTomato cells measured by flow cytometry. (D) Micrographs of consecutive sections showing that CD31 staining (left) and RFP staining (right) do not show a clear correlation with EF5 staining (middle). Scale bars: 500 µm (top row), 50 µm (bottom row). TAM, tamoxifen.

Post-hypoxic H1299-MR cells proliferate faster than non-hypoxic tumour cells

Next, we assessed the fate of the tdTomato+ post-hypoxic tumour cells. 5-Ethynyl-2′-deoxyuridine (EdU) was administered to mice 3 h before sacrifice, and proliferation in xenografts was measured by flow cytometric analysis of EdU incorporation. At all measured time points, tdTomato+ cells proliferated faster than tdTomato– cells, comprising both non-hypoxic tumour cells and host cells within the tumour microenvironment (Fig. 4A). This was confirmed by immunofluorescent staining of EdU on 4% paraformaldehyde (PFA)-fixed frozen sections (Fig. 4B; Fig. S5A). Fig. S5B shows that EdU background staining is not significantly higher in tdTomato cells than in all cells. When tumour cells were gated separately from host cells using a human-nuclei-specific antibody (Fig. 4C), tdTomato+ cells also proliferated faster than tdTomato− cells (Fig. 4D). These results indicate that tumour cells that were exposed to hypoxia proliferate faster than tumour cells that were not.

Fig. 4.
Fig. 4.

Post-hypoxic H1299-MR cells proliferate faster than non-hypoxic tumour cells. (A,B) EdU assay showing that tdTomato+ cells proliferated faster than the tdTomato− population as measured by flow cytometry (A) and immunofluorescence (B). (C) Gating strategy of EdU incorporation in tdTomato− and tdTomato+ human cells (RL1-A+). (D) EdU proliferation assay showing that tdTomato+ human cells proliferated faster than the tdTomato− human cells. Dots represent individual mice and paired observations were connected with a line. n.s., non-significant; *P<0.05, **P<0.01, ***P<0.001 as determined by two-way ANOVA followed by Bonferroni's multiple comparison. TAM, tamoxifen.

Increased proliferation of post-hypoxic H1299-MR tumour cells is a non-cell-autonomous feature

To address whether the increased proliferation was a cell-autonomous acquired and stable feature of post-hypoxic tumour cells, H1299-MR xenografts were excised at 5-17 days after administration of tamoxifen and single-cell suspensions were cultured ex vivo. Antibiotic selection enriched for tumour cells and the percentage of tdTomato+ cells in culture increased initially, after which it stabilised (Fig. 5A). EdU incorporation showed that tdTomato+ and tdTomato– cells proliferated at the same rate at all passages (Fig. 5B). H1299-MR cells were also incubated at 21% and 0.2% O2 with 200 nm 4-OHT for 24 h, mixed in a 1:1 ratio and grown in Dulbecco's modified Eagle medium (DMEM) containing 1% fetal bovine serum (FBS). Approximately 20-30% of the cells were tdTomato+ and expression did not change as measured by flow cytometry after 3 and 15 days, indicating that proliferation of tdTomato+ and tdTomato– cells was similar in vitro (Fig. 5C). These results show that tumour cells previously exposed to hypoxia in vivo do not proliferate faster ex vivo, and that the observed increased proliferation of post-hypoxic tumour cells is influenced by factors in the tumour microenvironment.

Fig. 5.
Fig. 5.

Post-hypoxic tumour cells and non-hypoxic cells proliferate at similar rates ex vivo and in vitro. (A,B) Cells isolated from H1299-MR xenografts were cultured ex vivo under geneticin and blasticidin selection. Individual tumours were depicted and connected with a line. (A) tdTomato expression initially increased and stabilised after several cultured passages as measured by flow cytometry. (B) In ex vivo culture, tdTomato+ and tdTomato− cells proliferate similarly, as shown by EdU incorporation measured by flow cytometry. (C) H1299-MR cells were incubated at 21% and 0.2% O2 with 200 nm 4-OHT for 24 h before being mixed in a 1:1 ratio and grown in DMEM containing 1% FBS. tdTomato expression was then analysed and proved similar after 3 and 15 days.

Intravital imaging visualises hypoxic cell tracing at the single-cell level in xenografts

Next, we used intravital microscopy to identify hypoxia lineage tracing in vivo in xenograft tumours. H1299-MR xenografts were covered by an imaging window to allow intravital imaging by multiphoton microscopy and tumours were followed for up to 18 days after administration of tamoxifen (Fig. S6). FITC-Dextran or qTracker 705 were injected intravenously and tumours were imaged for vessel perfusion, eGFP and tdTomato, and by second harmonic generation microscopy (Fig. 6A; Fig. S6A-D). Fig. 6A shows an example of a tumour imaged 4 days after administration of tamoxifen and other time points are shown in Fig. S6D. tdTomato was not observed before administration of tamoxifen (Fig. S6B-D). Occasionally eGFP+ cells were observed (Fig. 6A, arrows). These results demonstrate that we were able to track post-hypoxic tumour cells in a spatiotemporal manner using intravital microscopy.

Fig. 6.
Fig. 6.

H1299-MR xenografts visualised using intravital microscopy. (A) 3D maximum-intensity projection (left) and one slice of the same tumour (right) imaged 4 days after administration of tamoxifen. Perfused vessels are shown in purple, eGFP+ cells in green, tdTomato+ cells in red and collagen in cyan (second harmonic generation microscopy, right panel only). Channel arithmetics was applied using MATLAB to subtract GFP bleed through into the tdTomato channel and tdTomato bleed through into the Qtracker 705 channel. Scale bars: 500 µm (B) Vessel segmentation (grey) and tdTomato+ cells shown in the colour spectrum, indicating the distance to perfused vessels (0 µm in purple to 151 µm in red). Scale bars: 500 µm (left) and 50 µm (right). (C) Perfused vessel volume as a percentage of total tumour volume in four mice followed over time. TAM, tamoxifen.

To assess tumour perfusion, we injected qTracker 705 and segmented and reconstructed the vessels with Imaris (Fig. 6B). The colour spectrum indicates the distance of tdTomato+ cells to perfused vessels. The median distance of tdTomato+ spots in this tumour was 27.4 µm, with a distribution of 0-151 µm. These results indicate that tdTomato cells were located in proximity to, as well as further away from, the vessels (Fig. 6B, right); however, this was not normally distributed. Cells were more likely to be close to a vessel, with 50% of the cells being within 27.4 µm of a vessel in the displayed tumour and an average of 35.5 µm for all tumours (not shown). Purple cells (Fig. 6B, right) with a distance of 0 µm from a vessel appeared to be touching the vessel, rather than circulating inside it. Total vessel perfusion was calculated from the segmented vessels and remained constant over time in two of the four mice (Fig. 6C, curve A and B, corresponding to mice represented in Fig. S6A,B), whereas vessel volume decreased in mouse C and D (Fig. S6C,D). Overall, tumours seemed well perfused, which is in line with total vessel area as shown by CD31 staining (Fig. 2G).

DISCUSSION

Here, we describe a novel system to lineage trace hypoxic cells. We show that the system is robust in vitro with hypoxia-regulated eGFP expression and constitutive tdTomato labelling upon addition of tamoxifen in the progeny of these hypoxic tumour cells. We also see that the MARCer reporter system does not interfere with endogenous HIF-1α protein expression and the transcription of the HIF target gene VEGF, and this expression is only mildly affected by tamoxifen and only during the short period of tamoxifen administration. In vivo, tdTomato expression was induced; however, the amount of expression or the distribution did not correlate with EF5 positivity at any of the investigated time points. Intravital imaging showed that the tumours were well perfused, which is supported by the regular distribution of vessels throughout the tumour and the lack of correlation between vessels and EF5+ areas, as shown by immunofluorescence, suggesting also alternative mechanisms of HIF stabilisation.

With the H1299-MR model, in vitro exposure to hypoxia induced eGFP expression. However, eGFP was barely detectable in vivo with our microscopy systems However, given the clear presence of hypoxic areas as shown by EF5 staining, lack of HIF-1α – and thus eGFP – seems unlikely. This is likely to be due to the requirement of O2 for GFP folding and fluorescence (Heim et al., 1994; Kumagai et al., 2013), making it a suboptimal fluorescent marker to track current hypoxia. On the other hand, Godet et al. (2019) were able to visualise GFP under 0.5% O2. Also, processing of the samples exposes them to atmospheric oxygen, possibly introducing enough oxygen for GFP maturation ex vivo. Despite these limitations we were able to detect eGFP in H1299-MR xenografts using immunofluorescence and intravital microscopy.

Whether limited eGFP expression in our model is related to lack of expression or lack of visibility requires further investigation. An alternative approach could be to replace eGFP with fluorescent proteins not requiring oxygen such as UnaG (Kumagai et al., 2013). Possibly, eGFP expression is truly low in the currently studied tissues, which could be due to the length of time the cells are exposed to cycling hypoxia, not allowing enough time for sufficient MARCer accumulation before re-oxygenation and MARCer degradation. This is supported by our current finding that the amount of EF5 expressed in the tissue does not correlate with the number of tdTomato+ cells found in the tissue. An alternative explanation is that H1299 NSCLC cells express high levels of ROS, a potent activator of HIF-1α (Jung et al., 2008; Lee et al., 2010). Activation of HIF via ROS could partially explain the lack of overlap and correlation between EF5, HIF-eGFP and tdTomato labelling.

Surprisingly, neither the fraction of tdTomato+ cells and extent of EF5, nor the distance of those cells to EF5 correlated significantly, indicating that post-hypoxic tumour cells are randomly distributed with regard to the current hypoxic status of the tumour. This may be due to the dynamic nature of hypoxia in tumours and the time of assessment, i.e. the time after which the labelled cells were exposed to hypoxia, at least 48 h after tamoxifen administration. Because the MARCer construct is constitutively expressed, short episodes of hypoxia could induce labelling, but this might not be seen in proximity to EF5 due to re-oxygenation between the time tamoxifen was given and injection of EF5. Other research has also shown that hypoxic cells move out of hypoxic EF5+ or pimonidazole+ areas (Harada et al., 2012; Erapaneedi et al., 2016; Conway et al., 2018; Godet et al., 2019), followed by random distribution. The transient nature of the hypoxic state may explain that the induction of tdTomato expression does not correlate with the level of acute hypoxia 2, 5, 9, 16 or 21 days later. One way to further investigate this would be through the use of a second marker of hypoxia, given together with tamoxifen. This would allow visualisation of the hypoxia dynamics and see the change in hypoxia between labelling and endpoint. Taken together, EF5 reports on chronic severe hypoxia and anoxia, whereas HIF labelling captures also transient tumour hypoxia at moderate O2 levels. It also seems evident that many cells that have previously been exposed to hypoxia have redistributed to much less hypoxic regions.

In preliminary results with this system, it was apparent that a greater proportion of post-hypoxic cells tdTomato+ cells were undergoing proliferation compared to the non-hypoxic cells. In a range of common cancer types, HIF-1α was positively associated with the proliferation marker Ki67 (Mki67) (Zhong et al., 1999), and several studies report that HIF overexpression in cells can promote cell proliferation (Medici and Olsen, 2012).

While many cell types including cancer cells proliferate more slowly under hypoxia, here we are tracking the uptake of EdU by cells previously exposed to hypoxia. Whether this enhanced proliferation proves to be generalisable remains to be investigated, but might help explain why hypoxia can trigger more aggressive tumours (Hubbi and Semenza, 2015; Al Tameemi et al., 2019). Blouw et al. (2003) found a microenvironment-dependent effect of HIF-1α knockdown on tumour progression that might be relevant here. Koshiji et al. (2004) and Hubbi et al. (2013) showed that HIF-1α stabilisation induced cell cycle arrest, whereas in our model, HIF-1α was most likely degraded at the time we measured proliferation. It remains to be investigated what mechanisms are responsible for the long-term effect of hypoxia on proliferation in post-hypoxic tumour cells and whether this is dependent on HIF-1α. The H1299-MR model proves to be a promising tool to study this and other long-term effects of hypoxia including its role in metabolic plasticity and metastasis. Moreover, our finding that post-hypoxic tumour cells proliferated faster in vivo but not in vitro or ex vivo demonstrate that this acquired feature is unstable and non-cell autonomous. It will be of interest to identify what factors in the tumour microenvironment contribute to this.

Other approaches exploiting fluorescent markers driven by hypoxia-responsive elements and oxygen-dependent degradation domains have been described (Erapaneedi et al., 2016; Wang et al., 2016). Using intravital microscopy, Wang et al. (2016) visualised migration of individual normoxic and hypoxic MDA-MB-231 cells in a xenograft model. Similar to our findings, they also reported the presence of hypoxic cells both in proximity and distant from blood vessels. However, they did not quantify whether the distance was different from normoxic cells and, different to our current study, Wang et al. (2016) studied cells currently experiencing hypoxia, whereas we mainly focused on post-hypoxic cells. Tracing of recently re-oxygenated cells was also performed by Erapaneedi et al. (2016); however, their system using the fluorescent marker mOrange is dependent on PEST-sequence-dependent decay, making it less robust and more challenging to visualise by intravital microscopy, whereas we show stable expression of tdTomato for at least 4 weeks in post-hypoxic cells. Thus, the HIF-MARCer system is a useful addition to the armamentarium to visualise hypoxic, HIF-expressing cells. We show here that H1299-MR cells are a valuable tool to study the long-term fate of hypoxic cells, for example by using intravital microscopy.

In conclusion, our results demonstrate that single-cell lineage tracing of post-hypoxic tumour cells using the H1299-MARCer system allows visualisation of their behaviour in living tumours using intravital microscopy. We provide a valuable tool to study the dissemination and treatment response of post-hypoxic tumour cells in vivo and ex vivo at single-cell resolution. Using this system, we provide evidence that post-hypoxic tumour cells may have a proliferative advantage over non-hypoxic tumour cells and that this is influenced by the tumour microenvironment.

MATERIALS AND METHODS

Generating the Lenti MARCer system

First, an eGFP CreERT2 fusion single primer PCR was performed on plasmid pL451-Dll1(GFP-ires-CreERT2), a kind gift from Johan van Es (van Es et al., 2012), with primer 5′-GGCATGGACGAGCTGTACAAGTCCAATTTACTGACCGTACAC-3′ and on pEGFP-C1 (Clontech) with primer 5′-GGCATGGACGAGCTGTACAAG-3′. After the reaction, these template plasmids were digested with DpnI, before mixing 1 μl of each reaction for a fresh PCR with primer pair 5′-GTGAGCAAGGGCGAGGA-3′ and 5′-CCAGACATGATAAGATACATTGATGAG-3′ to amplify the fusion product with proofreading Phusion DNA Polymerase (FynnZyme). This GFP-CreERT2 PCR fragment was gel purified, and T overhangs were added with normal Taq polymerase before sub cloning it in a pCR-XL-TOPO® vector (Invitrogen), generating pCR-GFP-CreERT2 vector. Afterwards, this vector was used as a template to generate in a similar approach the fusion with HIF-1α. A HIF-1α ∼1.5 kb guide DNA fragment was amplified from BAC clone RP11: 618G20 (GenBank: AL137129.4), using primers 5′-TGGATCCGAGCTCGGTACCATAGATCTGAACATTATAACTTGATAAATGAGG-3′ and 5′-AGCTCCTCGCCCTTGCTCACCTGGAATACTGTAACTGTGC-3′. The product, a fusion of HIF-1α in exon 12 with 20 nucleotides of the cDNA GFP, was cloned by use of the NEBuilder® HiFi DNA assembly cloning kit in the pCR-GFP-CreERT2 plasmid, generating pCR-HIF-LHA-GFP-CreERT2. On this plasmid, a single primer PCR with primer 5′-GCAAGCCCTGAAAGCGCAAG-3′ and the cDNA human HIF-1α in a p3XFLAG-CMV™-10 expression vector (Sigma-Aldrich, St Louis, MO, USA) (Gort et al., 2008) was used as a template with a complementary single primer PCR with primer 5′-CTTGCGCTTTCAGGGCTTGC-3′. After the reaction, the template plasmids were digested with DpnI, before mixing 1 μl of each reaction for a fresh PCR with primer pair 5′-GATATCGGTACCAGTCGACTC-3′ and 5′-GTGGTACCCGTCATCAAGCTGTGGCAGGGA-3′, amplifying the MARCer cDNA (Fig. 1A, top), which was subcloned in a pCR®-Blunt II-TOPO® vector, generating pCR-BluntII-MARCer. Flanked by BstXI sites, the MARCer cDNA was, after digestion, retrieved by gel purification to replace luciferase in the BstXI-digested pLenti CMV V5-LUC Blast (w567-1), Addgene plasmid #21474, deposited by Eric Campeau (Campeau et al., 2009), generating pLenti-CMV-MARCer-Blast. This plasmid expresses amino acids 1-603 of the human HIF-1α protein fused to eGFP-CreERT2.

The Ai65(RCFL-tdT) targeting vector, Addgene plasmid #61577, deposited by Hongkui Zeng (Li et al., 2015), was digested with BstBI-AscI, and a 6267 bp fragment was isolated and cloned into an empty BstBI-AscI-digested pLVX-puro vector with an introduced unique AscI site to fuse proteins to FLAG and HA tags at the carboxy terminus (Groot et al., 2014). Next, the FLAG-HA-PGK-Puro-WPRE fragment was removed from this vector with an AscI-KpnI digest followed by blunting of the DNA ends with Mung Bean and ligated back. Finally, the FRT-STOP-FRT cassette was removed with a digest with XhoI and the vector was back ligated to generate the pLV(cmv)-NEO-SFS-tdTomato Cre reporter plasmid. The full integrity of all constructs was confirmed by DNA sequencing.

Generation of the H1299-MR cell line

Viral particles were produced using viral vectors and packaging plasmids in 293FT cells as previously published (Groot et al., 2014). H1299 cells on which we performed STR analysis were first transduced with MARCer viruses and cells were selected with 10 µg/ml blasticidin in the 10% FBS RPMI culture medium, supplemented with penicillin/streptomycin. Transduced cells were single-cell seeded to form clones on 15 cm dishes. Next, clones were harvested by use of glass clonal cylinders (Sigma-Aldrich) with Baysilone-Paste (GE Bayer Silicones) and expanded. Clones were split and transiently transfected with the reporter plasmid described above and screened for their switching capacity with the addition of 100 nM DFO and 100 nM 4-OHT (H7904-5MG, Sigma-Aldrich). We identified clone number 12 to show most tdTomato expression after treatment. Next, clone 12 was subsequently transduced with SFS-tdTomato viruses and clones were selected after this second transduction and were selected with 10 µg/ml blasticidin and 1000 µg/ml G418 in the 10% FCS RPMI culture medium, supplemented with penicillin/streptomycin. The polyclonal cell population was exposed to 1% of oxygen for 24 h in a Russkinn INVIVO 1000 hypoxic chamber. Next, the recovered cells were passed in culture at normoxic conditions for 2 days. To these cells, 100 nM 4-OHT was added to the medium for 24 h. To select for cells without leakage, cells were single-cell seeded and colourless clones were picked as described above. Clones were expanded and split into 250,000 cells per six-well plate and exposed to 200 nM 4-OHT under hypoxia and normoxia for 24 h, before being trypsinised and expanded for 3 days in culture flasks. We identified H1299 clone 12.3 (H1299-MR) as a robust hypoxia reporter cell line that we characterised and used in our further experiments.

Cell culture and hypoxia

H1299-MR cells were cultured in 10% FBS (Gibco) RPMI culture medium (Sigma-Aldrich) supplemented with 1% penicillin/streptomycin (Sigma-Aldrich), 10 µg/ml blasticidin (InvivoGen) and 1000 µg/ml G418 (Sigma-Aldrich). Cells were regularly tested for mycoplasma and incubated in a humidified incubator or hypoxia chamber Ruskinn InVivo 300 (Fig. 1C, left, D, left, E,F; Fig. S1A,B,G,H) or InVivo 1000 (Fig. 1B,C, right, D, right, Fig. 5C; Fig. S1C-F) with or without 4-OHT. Images during cell culture were taken with a Nikon eclipse Ts2 microscope.

Western blotting

Cells were lysed in RIPA buffer, containing 50 mM Tris·HCl, 0.5% DOC, 0.1% SDS, 1 mM EGTA, 2 mM EDTA, 10% glycerol, 1% Triton X-100, 150 mM NaCl and 1 mM PMSF, and protease inhibitors (ROCHE pill Complete Inhibitor). Protein concentrations were determined with the Bradford Protein Assay (Bio-Rad). Proteins (30 g) were separated by 6% SDS-PAGE and transferred to a PVDF membrane. The membrane was blocked with 5% non-fat dry milk (Marvel) and subsequently incubated (overnight, 4°C) with primary antibodies anti-HIF-1α (1:1000; #610959, BD Biosciences) and anti-lamin A (1:1000; #L1293, Sigma-Aldrich), and then horseradish peroxidase-linked secondary antibodies (horse anti-mouse and horse anti-rabbit; 1:2500; Cell Signaling Technology). ECL Prime Western Blotting Detection Reagent (GE Healthcare) was used for visualisation.

RNA isolation and quantitative PCR

mRNA was extracted using the Nucleospin RNA II kit (Bioke), and cDNA conversion was performed using an iScript cDNA synthesis kit (Bio-Rad), according to the manufacturer's instructions. Quantitative PCR was performed on a CFX96 (Bio-Rad). The expression of VEGF (F: 5′-GACTCCGGCGGAAGCAT-3′; R: 5′-TCCGGGCTCGGTGATTTA-3′) was detected with SYBR Green I (Eurogentec). Gene expression was normalised to Rpl13a (F: 5′-CCGGGTTGGCTGGAAGTACC-3′; R: 5′-CTTCTCGGCCTGTTTCCGTAG-3′) mRNA expression.

Mice

All animal studies were performed according to the Animals Scientific Procedure Act 1986 (UK) and approved by local ethical review. Female Balb/c nude mice were obtained from Envigo and kept in individually ventilated cages with unlimited supply of food and water and 12 h light-dark cycles, and mice were weighed twice a week. H1299-MR cells were harvested, dissolved in a single-cell suspension with Matrigel (Corning Life Sciences, 1:1) and 106 cells were injected subcutaneously into the flank of 6- to 10-week-old mice. Once tumours reached ∼100 mm3, tamoxifen (TAM, Sigma-Aldrich) was dissolved in vegetable oil containing 5% ethanol and administered through oral gavage. At the end of the experiment, mice were injected intraperitoneally with EF5 [2-(2-nitro-1/-/-imidazol-l-yl)-N-(2,2,3,3∼-pentafluoropropyl)acetamide], a nitroaromatic compound stabilised in the absence of oxygen (Lord et al., 1993), a kind gift from Prof. Cameron Koch (University of Pennsylvania, Philadelphia, PA, USA) and EdU (Santa Cruz Biotechnology) 3 h before sacrifice. Tumours were harvested, rinsed in PBS, cut in half and processed for flow cytometry or immunofluorescence.

Flow cytometry

Tumours were collected, halved, kept in Hanks’ balanced salt solution (HBSS; Gibco) and chopped into small pieces using a scalpel. Tumours were then digested in HBSS (Gibco) containing Collagenase Type 2 (Worthington Biochemical Corporation) and DNAse I (Thermo Fisher Scientific) for 40 min at 37°C in a shaking incubator. Cells were filtered through a 50 µm strainer (Sysmex Partec) and rinsed with FACS buffer (PBS containing 5% FBS) and centrifuged for 5 min at 300 g, 4°C and rinsed again. Cells were incubated for 15 min with LIVE/DEAD Fixable Violet Dead Cell Stain (Thermo Fisher Scientific), and a maximum of 2×106 cells was used for EdU staining using the Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay according to manufacturer's instructions (Thermo Fisher Scientific). The remaining cells were fixed using intracellular fixation buffer (1:1 in PBS, Thermo Fisher Scientific) for ∼10 min at room temperature (RT). Cells were stored in IC fixation buffer at 4°C until analysis on the Attune NxT Flow Cytometer (Thermo Fisher Scientific), when they were centrifuged for 5 min at 400 g and dissolved in FACS buffer. For compensation purposes, H1299-MR cells were cultured in vitro and subjected to DFO treatment (eGFP, channel BL-1), TAM+hypoxia and re-oxygenation (tdTomato, channel YL-1), 5 min at 65°C (LIVE/DEAD, channel VL-1, 1:1 with untreated cells), EdU (Click-iT assay, channel BL-1) or left untreated (unstained control and human nuclei, channel RL-1). When stained for human nuclei (1:100; MAB1281, Merck Millipore; Fig. 4C,D), this was performed for 30 min at RT in the dark after EdU staining (Click-iT Assay) and blocking. AF647 donkey anti-mouse IgG (1:500; Thermo Fisher Scientific) was used as a secondary antibody.

Cells cultured in vitro that were used for flow cytometry were rinsed and scraped in PBS, and added to IC fixation buffer (1:1 in PBS) inside the hypoxia chamber. They were then taken out of the chamber and incubated, together with cells not exposed to hypoxia, for ∼30 min at RT. Cells were stored in IC fixation buffer at 4°C until analysed, they were centrifuged for 5 min at 400 g and dissolved in FACS buffer. An example of the gating strategy was shown in Fig. 1C,D and analyses were performed in FlowJo (BD).

Ex vivo cell culture

When cells from xenografts were cultured ex vivo, tumours were harvested and put in RPMI complete medium without selection antibiotics. They were then digested as described above. From this point, cells were kept under sterile conditions, filtered through a 30 µm strainer (Sysmex Partec) and rinsed with PBS containing 2% BSA and 5 mM EDTA (both Sigma-Aldrich). After centrifugation for 5 min, 300 g at 4°C, the pellet was resuspended and incubated for 3 min in red cell lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA). Cells were rinsed twice with PBS/BSA/EDTA and dissolved in PBS. Half of the cells was taken into culture with RPMI complete medium and 10 µg/ml blasticidin and 1000 µg/ml G418 and the other half was stained for LIVE/DEAD, fixed and analysed by flow cytometry. At several culture passages, cells were harvested with Trypsin/EDTA (Sigma-Aldrich), filtered through a 30 µm strainer and stained for LIVE/DEAD and EdU as described above, and analysed by flow cytometry.

Immunofluorescence and microscopy

Tumour halves were rinsed in PBS and fixed for 3-4 h in 4% PFA at 4°C. They were transferred to 30% sucrose in PBS solution and kept overnight in the fridge and consecutively snap frozen in OCT embedding medium (Thermo Fisher Scientific) and stored at −20°C until cutting. Cryosections (10 µm) were cut using a Bright Cryostat or a Leica CM1950, dried overnight at 37°C and stored at −80°C until staining.

Sections were allowed to dry at room temperature for at least 30 min, rinsed in PBS and permeabilised with 0.5% Triton X-100 in PBS. For staining of CD31, 5% BSA (Sigma-Aldrich) and 5% donkey serum (Sigma-Aldrich) were added to the permeabilisation solution and this was also used for blocking for 1 h at RT. Blocking for RFP staining was done with 10% normal goat serum (Sigma-Aldrich) in PBS for 1 h at RT and with TNB blocking buffer (PerkinElmer) for 30 min for EF5 staining. Staining was performed overnight at 4°C with Cy5-conjugated EF5 antibody or Cy5-EF5 antibody containing competitor (both purchased from University of Pennsylvania and diluted 1:1 in PBS), rabbit anti-RFP (600-401-379, Rockland) or rabbit IgG (BD Biosciences) at 1:500 in PBS, and goat anti-CD31 (AF3628, R&D Systems) or goat IgG (R&D Systems) at 1 µg/ml. Sections stained for EF5 were washed with PBS/Tween 20 0.3% twice for 45 min. Sections stained for RFP and CD31 staining were washed 3× in PBS and incubated for 30 min at RT with secondary antibodies AF633 goat anti-rabbit and AF647 donkey anti-goat, respectively, at 1:500 dilution. The Click-iT EdU Cell Proliferation Kit for Imaging (Thermo Fisher Scientific) was used according to the manufacturer's instructions, and a solution containing only the Alexa Fluor picolyl azide in PBS/BSA 3% was used as a negative control. All sections were counterstained with Hoechst 33342 (Thermo Fisher Scientific) and mounted in Prolong Diamond Antifade Mountant (Thermo Fisher Scientific). Entire sections were imaged using a Nikon-NiE epifluorescence microscope with a 20× objective. Images were stitched with NIS Elements (Nikon) and processed with Imaris software (Bitplane). To get an overview of the entire tumour, one to five sections per tumour, separated by ∼1 mm, were analysed and the average was displayed.

Abdominal imaging window and intravital microscopy

Under inhalation anaesthesia with isoflurane, an imaging window was placed onto the abdominal wall of a mouse as previously described (Ritsma et al., 2013) with the following adjustments. A titanium window was used and a coverslip was glued on top with BBRAUN Histoacryl (Akin Global Medical). Vetergesic was injected subcutaneously as analgesic. An incision was made in the skin, after which 5×105 H1299-MR cells in 30% Matrigel in 5 µL were injected into the thin fat layer above the abdominal muscle. The window was stitched to the muscle layer using 5-0 silk and then secured to the skin with 5-0 prolene sutures (Ethicon). After ∼6 weeks, when tumours became visible by eye, 10 mg tamoxifen in 100 µl 5% ethanol/oil mixture was administered by oral gavage. At every imaging session, windows were carefully cleaned with an insulin syringe using 0.9% NaCl and all liquid and air between the coverslip and the tumour was removed. FITC-Dextran (MW 500, Sigma-Aldrich) or Qtracker 705 (Thermo Fisher Scientific), diluted 1:10 in sterile saline, was administered via the cannulated tail vein by a bolus injection of 2×12.5 µl, followed by a rate of 70 µl/h using an automated pump (Harvard Instruments). Tumours were imaged using a ZEISS LSM 880 microscope with a Mai-Tai laser (Newport Spectra-Physics, 940 nm excitation) using a ZEISS 20×/1.0 NA water objective covered with ultrasound gel. For detection of Qtracker 705, a 670 nm shortpass filter was used, whereas bandpass filters of 457-487 nm were used for collagen (second harmonic generation microscopy, 2-HG), of 488-512 nm for eGFP/FITC and of 562.5-587.5 nm for detection of tdTomato. Tile scans were taken up to 350 µm deep with a voxel size of 0.83×0.83 in x-y and 5 µm in z, and stitched using ZEN Black Software (Carl ZEISS AG). Quantitative analyses were performed using Imaris.

Image analyses

All analyses were performed using Imaris software. First, the total tumour was outlined, background such as folds were excluded as much as possible and signal outside the tumour area was removed. For EF5 staining, hypoxic areas directly underneath the skin were excluded from the analysis. For stained sections, masks were created for Hoechst, tdTomato, and staining using the ‘surfaces’ or ‘spots’ functions and thresholds adjusted for each imaging session. All analyses were checked by eye and when the mask did not visually represent the positively stained area, the data were excluded from the analysis. A distance map from CD31+ and EF5+ areas was created using MATLAB and the median distance of tdTomato+ spots and Hoechst+ spots to CD31+ and EF5+ surfaces was calculated. For analyses of EdU, Hoechst+ cell surfaces were masked. These were filtered for an EdU+ threshold, either or not preceded by the tdTomato+ threshold and expressed as a percentage of total. RFP+ cells were also filtered by an intensity threshold on Hoechst+ surfaces.

For intravital images, channel arithmetic was applied using MATLAB to subtract GFP bleed through into the tdTomato channel and tdTomato bleed through into the Qtracker 705 channel. A surfaces mask was created on the Qtracker 705 signal and the perfused-vessel volume was expressed as a percentage of total tumour volume. A distance map from vessels was created using MATLAB and the distance of tdTomato+ spots to vessels was represented as a colour spectrum (0-151 µm).

Statistical analyses

Statistical analyses were performed using GraphPad Prism software. This was also used to create the figures that are showing the mean and individual measurements carried out in duplicate unless stated otherwise. Paired observations are displayed with a connecting line. The statistical tests performed are indicated for each figure and P<0.05 was considered significant.

Acknowledgements

We thank Prof. Cameron Koch at the University of Pennsylvania for providing EF5; Graham Brown and Rhodri Wilson at the Microscopy Scientific Research Facility for advice regarding microscopy and image analysis; John Prentice for help with creating the imaging windows; and Karla Watson, James Ward, and Magda Hutchins at Biomedical Services for technical support and animal care.

Footnotes

  • Competing interests

    The authors declare no competing or financial interests.

  • Author contributions

    Conceptualization: J.A.F.V., B.M., R.J.M., M.A.V.; Methodology: J.A.F.V., J.I., B.M., J.K., L.M.O.B., A.J.G.; Validation: J.A.F.V., J.I.; Formal analysis: J.A.F.V., J.I.; Investigation: J.A.F.V., J.I., B.M., J.K., L.M.O.B., A.J.G.; Resources: A.J.G.; Writing - original draft: J.A.F.V., J.I., A.J.G., M.A.V.; Writing - review & editing: J.A.F.V., J.I., B.M., J.K., A.J.G., R.J.M., M.A.V.; Visualization: J.A.F.V., J.I., A.J.G.; Supervision: R.J.M., M.A.V.; Project administration: M.A.V.; Funding acquisition: B.M., R.J.M., M.A.V.

  • Funding

    J.I., A.J.G. and L.M.O.B. were supported by the H2020 European Research Council under the European Union H2020 research and innovation programme (grant 617060 to M.A.V.). The research leading to these results has also received funding from the People Programme (FP7 People: Marie-Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013) under REA grant agreement no. 625631 to B.M. R.J.M. received funding from Cancer Research UK (grant C5255/A15935).

  • Supplementary information

    Supplementary information available online at https://dmm.biologists.org/lookup/doi/10.1242/dmm.044768.supplemental

  • Received March 3, 2020.
  • Accepted June 8, 2020.
http://creativecommons.org/licenses/by/4.0

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

References

  1. ↵
    1. Al Tameemi, W.,
    2. Dale, T. P.,
    3. Al-Jumaily, R. M. K. and
    4. Forsyth, N. R.
    (2019). Hypoxia-Modified Cancer Cell Metabolism. Frontiers in Cell and Developmental Biology, 7, 1-15.
    OpenUrlCrossRef
  2. ↵
    1. Blouw, B.,
    2. Song, H.,
    3. Tihan, T.,
    4. Bosze, J.,
    5. Ferrara, N.,
    6. Gerber, H.-P.,
    7. Johnson, R. S. and
    8. Bergers, G.
    (2003). The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133-146. doi:10.1016/s1535-6108(03)00194-6
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Brahimi-Horn, M. C.,
    2. Chiche, J. and
    3. Pouysségur, J.
    (2007). Hypoxia and cancer. J. Mol. Med., 85, 1301-1307. doi:https://doi.org/doi:10.1007/s00109-007-0281-3
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Campeau, E.,
    2. Ruhl, V. E.,
    3. Rodier, F.,
    4. Smith, C. L.,
    5. Rahmberg, B. L.,
    6. Fuss, J. O. and
    7. Kaufman, P. D.
    (2009). A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One, 4. doi:https://doi.org/10.1371/journal.pone.0006529
    OpenUrlCrossRef
  5. ↵
    1. Conway, J. R. W.,
    2. Warren, S. C.,
    3. Herrmann, D.,
    4. Murphy, K. J.,
    5. Cazet, A. S.,
    6. Vennin, C. and
    7. Timpson, P.
    (2018). Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Cell Rep. 23, 3312-3326. doi:https://doi.org/doi:10.1016/j.celrep.2018.05.038
    OpenUrlCrossRef
  6. ↵
    1. Dewhirst, M. W.
    (2009). Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat. Res., 172, 653-665. doi:https://doi.org/doi:10.1667/RR1926.1
    OpenUrlCrossRefPubMed
  7. ↵
    1. Dubois, L. J.,
    2. Lieuwes, N. G.,
    3. Janssen, M. H. M.,
    4. Peeters, W. J. M.,
    5. Windhorst, A. D.,
    6. Walsh, J. C. and
    7. Lambin, P.
    (2011). Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for imaging. Proc. Natl Acad. Sci. USA, 108, 14620-14625. doi:https://doi.org/doi:10.1073/pnas.1102526108
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Erapaneedi, R.,
    2. Belousov, V. V.,
    3. Schäfers, M. and
    4. Kiefer, F.
    (2016). A novel family of fluorescent hypoxia sensors reveal strong heterogeneity in tumor hypoxia at the cellular level. EMBO J., 35, 102-113. doi:https://doi.org/10.15252/embj.201592775
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Fleming, I. N.,
    2. Manavaki, R.,
    3. Blower, P. J.,
    4. West, C.,
    5. Williams, K. J.,
    6. Harris, A. L. and
    7. Gilbert, F. J.
    (2015). Imaging tumour hypoxia with positron emission tomography. Br. J. Cancer, 112, 238-250. doi:https://doi.org/doi:10.1038/bjc.2014.610
    OpenUrlCrossRefPubMed
  10. ↵
    1. Fyles, A. W.,
    2. Milosevic, M.,
    3. Wong, R.,
    4. Kavanagh, M.-C.,
    5. Pintilie, M.,
    6. Sun, A. and
    7. Hill, R. P.
    (1998). Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48, 149-156. doi:https://doi.org/doi:10.1016/S0167-8140(98)00044-9
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Giatromanolaki, A.,
    2. Koukourakis, M. I.,
    3. Sivridis, E.,
    4. Turley, H.,
    5. Talks, K.,
    6. Pezzella, F. and
    7. Harris, A. L.
    (2001). Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85, 881-890. doi:https://doi.org/doi:10.1054/bjoc.2001.2018
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Godet, I.,
    2. Shin, Y. J.,
    3. Ju, J. A.,
    4. Ye, I. C.,
    5. Wang, G. and
    6. Gilkes, D. M.
    (2019). Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis. Nat. Commun. 10, 291. doi:https://doi.org/doi:10.1038/s41467-019-12412-1
    OpenUrlCrossRef
  13. ↵
    1. Gort, E. H.,
    2. Van Haaften, G.,
    3. Verlaan, I.,
    4. Groot, A. J.,
    5. Plasterk, R. H. A.,
    6. Shvarts, A. and
    7. Vooijs, M.
    (2008). The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2α. Oncogene 27, 1501-1510. doi:https://doi.org/doi:10.1038/sj.onc.1210795
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Gray, L. H.,
    2. Conger, A. D.,
    3. Ebert, M.,
    4. Hornsey, S. and
    5. Scott, O. C.
    (1953). The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26, 638-648. doi:https://doi.org/doi:10.1259/0007-1285-26-312-638
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Groot, A. J.,
    2. Habets, R.,
    3. Yahyanejad, S.,
    4. Hodin, C. M.,
    5. Reiss, K.,
    6. Saftig, P. and
    7. Vooijs, M.
    (2014). Regulated Proteolysis of NOTCH2 and NOTCH3 Receptors by ADAM10 and Presenilins. Mol. Cell. Biol. 34, 2822-2832. doi:https://doi.org/doi:10.1128/MCB.00206-14
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Harada, H.,
    2. Inoue, M.,
    3. Itasaka, S.,
    4. Hirota, K.,
    5. Morinibu, A.,
    6. Shinomiya, K. and
    7. Hiraoka, M.
    (2012). Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat. Commun. 3, 710-783. doi:https://doi.org/doi:10.1038/ncomms1786
    OpenUrlCrossRefPubMed
  17. ↵
    1. Heim, R.,
    2. Prashert, D. C.,
    3. Tsien, R. Y. and
    4. Kandel, E. R.
    (1994). Wavelength mutations and posttranslational autoxidation of green fluorescent protein (Aequorea victoria/blue fluorescent protein/Escherichia coli/imidazolidinone). Biochemistry 91, 12501-12504.
    OpenUrl
  18. ↵
    1. Hubbi, M. E. and
    2. Semenza, G. L.
    (2015). Regulation of cell proliferation by hypoxia-inducible factors. American Journal of Physiology-Cell Physiology 309, C775-C782. doi:https://doi.org/doi:10.1152/ajpcell.00279.2015
    OpenUrlCrossRefPubMed
  19. ↵
    1. Hubbi, M. E.,
    2. Kshitiz, M. E.,
    3. Gilkes, D. M.,
    4. Rey, S.,
    5. Wong, C. C.,
    6. Luo, W. and
    7. Semenza, G. L.
    (2013). A nontranscriptional role for HIF-1α as a direct inhibitor of DNA replication. Sci. Signal. 6, ra10. doi:https://doi.org/doi:10.1126/scisignal.2003417
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Ioannou, M.,
    2. Papamichali, R.,
    3. Kouvaras, E.,
    4. Mylonis, I.,
    5. Vageli, D.,
    6. Kerenidou, T. and
    7. Koukoulis, G. K.
    (2009). Hypoxia inducible factor-1alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung 187, 321-329. doi:https://doi.org/doi:10.1007/s00408-009-9169-z
    OpenUrlCrossRefPubMed
  21. ↵
    1. Ivan, M.,
    2. Kondo, K.,
    3. Yang, H.,
    4. Kim, W.,
    5. Valiando, J.,
    6. Ohh, M. and
    7. Kaelin, J.
    (2001). HIFα targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292, 464-468. doi:https://doi.org/doi:10.1126/science.1059817
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Janssens, G. O.,
    2. Rademakers, S. E.,
    3. Terhaard, C. H.,
    4. Doornaert, P. A.,
    5. Bijl, H. P.,
    6. Van Ende, P.
    7. Den, and
    8. Kaanders, J. H.
    (2012). Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: Results of a phase III randomized trial. J. Clin. Oncol. 30, 1777-1783. doi:https://doi.org/doi:10.1200/JCO.2011.35.9315
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Jubb, A. M.,
    2. Buffa, F. M. and
    3. Harris, A. L.
    (2010). Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J. Cell. Mol. Med. 14, 18-29. doi:https://doi.org/doi:10.1111/j.1582-4934.2009.00944.x
    OpenUrlCrossRefPubMed
  24. ↵
    1. Jung, S.-N.,
    2. Yang, W. K.,
    3. Kim, J.,
    4. Kim, H. S.,
    5. Kim, E. J.,
    6. Yun, H. and
    7. Ha, J.
    (2008). Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis 29, 713-721. doi:https://doi.org/doi:10.1093/carcin/bgn032
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Kedrin, D.,
    2. Gligorijevic, B.,
    3. Wyckoff, J.,
    4. Verkhusha, V. V.,
    5. Condeelis, J.,
    6. Segall, J. E. and
    7. van Rheenen, J.
    (2008). Intravital imaging of metastatic behavior through a mammary imaging window. Nat. Methods 5, 1019-1021. doi:https://doi.org/doi:10.1038/nmeth.1269
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Koshiji, M.,
    2. Kageyama, Y.,
    3. Pete, E. A.,
    4. Horikawa, I.,
    5. Barrett, J. C. and
    6. Huang, L. E.
    (2004). HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23, 1949-1956. doi:https://doi.org/doi:10.1038/sj.emboj.7600196
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Kumagai, A.,
    2. Ando, R.,
    3. Miyatake, H.,
    4. Greimel, P.,
    5. Kobayashi, T.,
    6. Hirabayashi, Y. and
    7. Miyawaki, A.
    (2013). A bilirubin-inducible fluorescent protein from eel muscle. Cell 153, 1602-1611. doi:https://doi.org/doi:10.1016/j.cell.2013.05.038
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. LaGory, E. L. and
    2. Giaccia, A. J.
    (2016). The ever-expanding role of HIF in tumour and stromal biology. Nat. Cell Biol. 18, 356-365. doi:https://doi.org/doi:10.1038/ncb3330
    OpenUrlCrossRef
  29. ↵
    1. Lee, S. J.,
    2. Hwang, A. B. and
    3. Kenyon, C.
    (2010). Inhibition of respiration extends C. elegans life span via reactive oxygen species that increase HIF-1 activity. Curr. Biol. 20, 2131-2136.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Lehtiö, K.,
    2. Eskola, O.,
    3. Viljanen, T.,
    4. Oikonen, V.,
    5. Grönroos, T.,
    6. Sillanmäki, L. and
    7. Minn, H.
    (2004). Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 59, 971-982. doi:https://doi.org/doi:10.1016/j.ijrobp.2003.12.014
    OpenUrlCrossRefPubMed
  31. ↵
    1. Lord, E. M.,
    2. Harwell, L. and
    3. Koch, C. J.
    (1993). Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 53, 5721-5726.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Madisen, L.,
    2. Garner, A. R.,
    3. Shimaoka, D.,
    4. Chuong, A. S.,
    5. Klapoetke, N. C.,
    6. Li, L.,
    7. van der Bourg, A.,
    8. Niino, Y.,
    9. Egolf, L. and
    10. Monetti, C.
    (2015). Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. Neuron 85, 942-958. doi:https://doi.org/doi:10.1016/j.neuron.2015.02.022
    OpenUrlCrossRefPubMed
  33. ↵
    1. Medici, D. and
    2. Olsen, B. R.
    (2012). Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS One 7. doi:https://doi.org/10.1371/journal.pone.0042913
    OpenUrlCrossRef
  34. ↵
    1. Milosevic, M.,
    2. Warde, P.,
    3. Meńard, C.,
    4. Chung, P.,
    5. Toi, A.,
    6. Ishkanian, A. and
    7. Bristow, R.
    (2012). Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin. Cancer Res. 18, 2108-2114. doi:https://doi.org/doi:10.1158/1078-0432.CCR-11-2711
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Muz, B.,
    2. de la Puente, P.,
    3. Azab, F. and
    4. Azab, A. K.
    (2015). The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 83. doi:https://doi.org/10.2147/hp.s93413
    OpenUrlCrossRef
  36. ↵
    1. Nordsmark, M.,
    2. Bentzen, S. M.,
    3. Rudat, V.,
    4. Brizel, D.,
    5. Lartigau, E.,
    6. Stadler, P. and
    7. Overgaard, J.
    (2005). Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 77, 18-24. doi:https://doi.org/doi:10.1016/j.radonc.2005.06.038
    OpenUrlCrossRefPubMed
  37. ↵
    1. Overgaard, J.
    (2007). Hypoxic radiosensitization: Adored and ignored. J. Clin. Oncol. 25, 4066-4074. doi:https://doi.org/doi:10.1200/JCO.2007.12.7878
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Prabhakar, N. R. and
    2. Semenza, G. L.
    (2015). Oxygen Sensing and Homeostasis. Physiology 30, 340-348. doi:https://doi.org/doi:10.1152/physiol.00022.2015
    OpenUrlCrossRefPubMed
  39. ↵
    1. Ren, H.-Y.,
    2. Zhang, Y. H.,
    3. Li, H. Y.,
    4. Xie, T.,
    5. Sun, L. L.,
    6. Zhu, T. and
    7. Ye, Z. M.
    (2016). Prognostic role of hypoxia-inducible factor-1 alpha expression in osteosarcoma: A meta-analysis. OncoTargets and Therapy 9, 1477-1487. doi:https://doi.org/doi:10.2147/OTT.S95490
    OpenUrlCrossRef
  40. ↵
    1. Ritsma, L.,
    2. Steller, E. J. A.,
    3. Ellenbroek, S. I. J.,
    4. Kranenburg, O.,
    5. Borel Rinkes, I. H. M. and
    6. Van Rheenen, J.
    (2013). Surgical implantation of an abdominal imaging window for intravital microscopy. Nat. Protoc., 8, 583-594. doi:https://doi.org/doi:10.1038/nprot.2013.026
    OpenUrlCrossRefPubMed
  41. ↵
    1. Roig, E. M.,
    2. Yaromina, A.,
    3. Houben, R.,
    4. Groot, A. J.,
    5. Dubois, L. and
    6. Vooijs, M.
    (2018). Prognostic role of hypoxia-inducible factor-2α tumor cell expression in cancer patients: A meta-analysis. Front. Oncol. 8. doi:https://doi.org/10.3389/fonc.2018.00224
    OpenUrlCrossRef
  42. ↵
    1. Salem, A.,
    2. Asselin, M.-C.,
    3. Reymen, B.,
    4. Jackson, A.,
    5. Lambin, P.,
    6. West, C. M. L. and
    7. Faivre-Finn, C.
    (2018). Targeting hypoxia to improve non-small cell lung cancer outcome. J. Natl. Cancer Inst. 110, 14-30. doi:https://doi.org/doi:10.1093/jnci/djx160
    OpenUrlCrossRef
  43. ↵
    1. Spiegelberg, L.,
    2. Houben, R.,
    3. Niemans, R.,
    4. de Ruysscher, D.,
    5. Yaromina, A.,
    6. Theys, J. and
    7. Dubois, L. J.
    (2019). Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. Clin. Transl. Radiat. Oncol. 15, 62-69. doi:https://doi.org/doi:10.1016/j.ctro.2019.01.005
    OpenUrlCrossRef
  44. ↵
    1. Thomlinson, R. H. and
    2. Gray, L. H.
    (1955). The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy. Br. J. Cancer 9, 539-549. doi:https://doi.org/doi:10.1038/bjc.1955.55
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Van Cutsem, E.,
    2. Lenz, H.-J.,
    3. Furuse, J.,
    4. Tabernero, J.,
    5. Heinemann, V.,
    6. Ioka, T. and
    7. Bendell, J. C.
    (2016). MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). J. Clin. Oncol. 34, 4007. doi:https://doi.org/doi:10.1200/JCO.2016.34.15_suppl.4007
    OpenUrlCrossRef
  46. ↵
    1. van Es, J. H.,
    2. Sato, T.,
    3. van de Wetering, M.,
    4. Luybimova, A.,
    5. Gregorieff, A.,
    6. Zeinstra, L. and
    7. Clevers, H.
    (2012). Dll1 marks early secretory progenitors in gut crypts that can revert to stem cells upon tissue damage. Nat. Cell Biol. 14, 1099-1104. doi:https://doi.org/doi:10.1038/ncb2581
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    1. Vaupel, P. and
    2. Mayer, A.
    (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225-239. doi:https://doi.org/doi:10.1007/s10555-007-9055-1
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Wang, Y.,
    2. Wang, H.,
    3. Li, J.,
    4. Entenberg, D.,
    5. Xue, A.,
    6. Wang, W. and
    7. Condeelis, J.
    (2016). Direct visualization of the phenotype of hypoxic tumor cells at single cell resolution in vivo using a new hypoxia probe. IntraVital 5, e1187803. doi:https://doi.org/doi:10.1080/21659087.2016.1187803
    OpenUrlCrossRef
  49. ↵
    1. Wilson, W. R. and
    2. Hay, M. P.
    (2011). Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393-410. doi:https://doi.org/doi:10.1038/nrc3064
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    1. Zheng, S.-S.,
    2. Chen, X.-H.,
    3. Yin, X. and
    4. Zhang, B.-H.
    (2013). Prognostic significance of HIF-1α expression in hepatocellular carcinoma: a meta-analysis. PLoS One 8, e65753. doi:https://doi.org/doi:10.1371/journal.pone.0065753
    OpenUrlCrossRefPubMed
  51. ↵
    1. Zhong, H.,
    2. De Marzo, A. M.,
    3. Laughner, E.,
    4. Lim, M.,
    5. Hilton, D. A.,
    6. Zagzag, D. and
    7. Simons, J. W.
    (1999). Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59, 5830-5835.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top

RSSRSS

Keywords

 Download PDF

Email
RESEARCH ARTICLE
A lineage-tracing tool to map the fate of hypoxic tumour cells
Jenny A. F. Vermeer, Jonathan Ient, Bostjan Markelc, Jakob Kaeppler, Lydie M. O. Barbeau, Arjan J. Groot, Ruth J. Muschel, Marc A. Vooijs
Disease Models & Mechanisms 2020 13: dmm044768 doi: 10.1242/dmm.044768 Published 30 July 2020
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Alerts

Article navigation

Subject collections

Other journals from The Company of Biologists

Advertisement

DMM and COVID-19

We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.

Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.

Sustainable Conferencing with The Company of Biologists

A new initiative spearheaded by Directors Sally Lowell, Kate Storey, Alastair Downey and Holly Shiels will provide information, technology and grants to help the community run conferences in a more sustainable way. 

preLights - APCs donate their telomeres to promote T cell lifespan

Over on preLights, Giuseppina D'Alessandro discusses a new preprint from Vaz et al., which shows that resting T cells are still able to integrate APC telomeres.

A new C. elegans model of pheochromocytoma/paraganglioma

In November's Editor's choice, Krisztina Takács-Vellai and colleagues developed a new C. elegans model of pheochromocytoma/paraganglioma, an ultra-rare inherited neuroendocrine tumour syndrome, and identified an underlying metabolic mechanism of malignancy.

Interview – Gideon Hughes

Gideon Hughes is the first author of our current most-read article, which details a machine learning approach to study disordered movement in a zebrafish model of Parkinsons. Find out more about Gideon, his work and life away from the bench.